A Game-Changer for Cardiovascular Risk and Mortality The SELECT trial showed a 1.5% absolute and a 20% relative risk reduction in cardiovascular death, non-fatal MI, and non-fatal stroke
However, many researchers are concerned about potential ocular adverse effects with continued use of these medications, most notoriously the controversy about a potential increased risk of ischemic optic neuropathy that has generated several research papersoften contradictorysince last summer
To contextualize the pharmacological profile of Dihexa, laboratory investigators frequently run comparative assays against other well-characterized neurogenic and neuroprotective compounds within the PX1 Research catalog
Education, risks, and informed treatment choices For rybelsus, Southwestern Medical Center emphasizes plain-language guidance, structured headings, and direct next-step instructions
A 30-week randomized non-inferiority study comparing 2 mg once-weekly EX-LAR with 10 g twice-daily EX in 295 patients with T2DM
Benefits of exercise and astaxanthin supplementation: Are there additive or synergistic effects